Skip to main content
. 2010 Jan 29;159(3):495–501. doi: 10.1111/j.1476-5381.2009.00486.x

Figure 2.

Figure 2

Neuroprotection by exendin-4 (EX-4) in the 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. (A) EX-4 shows clear restoration of motor behaviour; (B) tissue dopamine (DA) content; (C) striatal tyrosine hydroxylase (TH) activity; (D) nigral TH immunoreactivity shown as a qualitative index of TH staining. In all groups, EX-4 or vehicle was given twice daily for 7 days after the initial 6-OHDA insult. In each case groups are made up of six rats per group and were subjected to one-way analysis of variance (anova) followed by a post hoc Bonferonni's Multiple Comparison Test (A–C). One-way anova revealed significant differences between treatments in for all of the parameters studied (A–C; P < 0.001). Bonferonni's Multiple Comparison Test revealed significant differences (*) from all other groups (A) and from sham or EX-4 treated groups (B and C). Data adapted from (Harkavyi et al., 2008). L-DOPA, L-3,4-dihydroxyphenylalanine; EX-9-39, exendin-(9,39).